# US 2020/0392218 A1 · Compositions and methods for reducing at least one symptom of human allergy to cats

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392218 A1
- Document ID: US20200392218A1
- Status: Published application
- Kind: A1
- Application number: 16/988,829
- Filed: 2020-08-10
- Published: 2020-12-17
- Earliest claimed: 2017-01-24
- Assignees: Societe des Produits Nestle S.A.
- Applicants: Société des Produits Nestlé S.A.
- Inventors: Timothy James Wooster; Ebenezer Satyaraj; Eddy Gombas; Beat Gerber
- Web page: https://patentgrep.com/patent/US20200392218A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2039/505: {comprising antibodies}
- C07K 2317/11: isolated from eggs
- C07K 2317/23: from birds
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Compositions and methods reduce symptoms of human allergy to cats. The effectiveness of a molecule which specifically binds to Feline domesticus allergen number 1 (Fel D1) is enhanced by prolonging the time the immunoglobulin stays within the mouth of a cat to whom the anti-Fel D1 molecule is administered in a pet food. The compositions and methods use a powder that is a dried hydrogel encapsulating the anti-Fel D1 molecule, and the hydrogel is based on gelatin, collagen peptides, or gelatin and collagen peptides; and carrageenan. The methods of making the powder provide a high encapsulation efficacy, sustained release of the anti-Fel D1 molecule in the cat's mouth, and oral adhesion of the anti-Fel D1 molecule in the cat's mouth.

## Claims

### Claim 1

A food grade powder providing sustained release of an anti-Fel D1 molecule, the food grade powder comprising a dried hydrogel and the anti-Fel D1 molecule; wherein the dried hydrogel comprises gelatin, collagen peptides, or gelatin and collagen peptides; and carrageenan; wherein the anti-Fel D1 molecule is encapsulated in the dried hydrogel.

### Claim 2 (depends on 1)

The food grade powder of claim 1, wherein the gelatin or the gelatin and collagen peptides are from Type A porcine gelatin having a positive charge at a pH below 7.0.

### Claim 3 (depends on 1)

The food grade powder of claim 1, wherein the carrageenan is selected from the group consisting of (i) kappa-carrageenan, (ii) iota-carrageenan, (iii) a physical mixture of kappa-carrageenan and iota-carrageenan and (iv) a co-polymer of kappa-carrageenan and iota-carrageenan.

### Claim 4 (depends on 1)

The food grade powder of claim 1, wherein the gelatin and the carrageenan are the only biopolymers in the dried hydrogel.

### Claim 5 (depends on 1)

The food grade powder of claim 1, wherein the dried hydrogel is a spray-dried hydrogel comprising the anti-Fel D1 molecule and 0.5 to 90 wt. % of gelatin, and the powder has a density of about 0.265 to about 0.3 g/cm3.

### Claim 6 (depends on 5)

The food grade powder of claim 5, wherein the gelatin and collagen peptides have a molecular weight between 2,000 and 1 million Daltons and a bloom value of 40 to 300.

### Claim 7 (depends on 5)

The food grade powder of claim 5, comprising 25.0 to 60.0 wt. % of the gelatin and 40 to 75 wt. % of a source of the anti-Fel D1 molecule.

### Claim 8

A method of making a food grade powder providing sustained release of an anti-Fel D1 molecule, the method comprising:
heating a solution comprising gelatin, carrageenan and the anti-Fel D1 molecule;
forming droplets of the heated solution;
gelling the droplets by subjecting the droplets to a gelling bath comprising salt or oil to form gelled beads in which the anti-Fel D1 molecule is encapsulated; and
drying the gelled beads to form the food grade powder.

### Claim 9 (depends on 8)

The method of claim 8, wherein the gelling bath comprises about 100 mM of potassium chloride, about 100 mM calcium chloride, or both.

### Claim 10 (depends on 8)

The method of claim 8, wherein the drying comprises subjecting the beads to fluid bed drying.

### Claim 11 (depends on 8)

The method of claim 8, wherein the gelatin and the carrageenan are the only biopolymers capable of gelling below 60° C. in the dried hydrogel.

### Claim 12

A method of making a food grade powder providing sustained release of an anti-Fel D1 molecule, the method comprising:
heating a solution comprising gelatin, carrageenan, and the anti-Fel D1 molecule;
extruding the heated solution to cool and shape the heated solution and form an extruded hydrogel in which the anti-Fel D1 molecule is encapsulated; and
drying the extruded hydrogel.

### Claim 13 (depends on 12)

The method of claim 12, wherein the extruding is performed by a tubular heat exchanger having a temperature of about 0.1° C. to about 35° C.

### Claim 14 (depends on 12)

The method of claim 12, further comprising immersing the extruded hydrogel in a composition comprising calcium, magnesium potassium, rubidium, or cesium before the drying.

### Claim 15 (depends on 12)

The method of claim 12, wherein the drying comprises subjecting the extruded hydrogel to a drying tunnel, oven, or fluid bed drier.

### Claim 16

A method of making a food grade powder providing sustained release of an anti-Fel D1 molecule, the method comprises spray drying a solution comprising the anti-Fel D1 molecule and 5.0 to 20.0 wt. % of gelatin and collagen peptides having a molecular weight between 2,000 and 1 million Daltons and or a bloom value of 40 to 300 to form a dried hydrogel in which the anti-Fel D1 molecule is encapsulated.

### Claim 17 (depends on 16)

The method of claim 16, wherein the gelatin and collagen peptides are the only biopolymers capable of gelling below 60° C. in the dried hydrogel.

### Claim 18 (depends on 16)

The method of claim 16, wherein the solution comprises 7.5 to 12.5 wt. % of the gelatin and 5 to 20 wt. % of a source of the anti-Fel D1 molecule.

### Claim 19 (depends on 1)

A method of reducing symptoms of human allergy to a cat, the method comprising orally administering to the cat an effective amount of the food grade powder of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the composition is administered as part of a pet food further comprising at least one component selected from the group consisting of protein, fat, carbohydrate, vitamin and mineral.
